Asked by: Wayne David (Labour - Caerphilly)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will take steps to help ensure eligible people with migraines can access NICE-approved calcitonin gene-related peptide antibody medicines.
Answered by Edward Argar
The National Institute for Health and Care Excellence (NICE) has published guidance recommending erenumab, galcanezumab and fremanezumab, all of which are calcitonin gene-related peptide antibody medicines, for preventing migraine in adults for routine funding in the National Health Service in England, subject to specified criteria. NHS England is legally required to fund medicines recommended in a NICE technology appraisal, usually within three months of final guidance. This funding requirement ensures that there is consistency of access for to NICE recommended medicines. The NHS Constitution states that patients have the right to drugs and treatments recommended by NICE for use in the NHS, if their doctor believes they are clinically appropriate.
Asked by: Wayne David (Labour - Caerphilly)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what comparative assessment he has made of outcomes in liver disease care in England compared to (a) Wales, (b) Scotland and (c) other comparable countries.
Answered by Maria Caulfield
Public Health England (PHE) has not made a direct comparison of outcomes in liver disease care in England, Scotland and Wales.
In 2017, PHE published the Second Atlas of Variation in risk factors and healthcare for liver disease in England. This included comparisons of liver disease outcomes across the European Union, in particular France and Sweden as comparable countries to the United Kingdom. The Second Atlas of Variation in risk factors and healthcare for liver disease in England is available at the following link:
https://fingertips.phe.org.uk/profile/atlas-of-variation
Asked by: Wayne David (Labour - Caerphilly)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the implications for his policies of the increasing trend in alcohol consumption and harm; and what steps his Department is taking to tackle that increase.
Answered by Jo Churchill
There is a programme of work underway to address alcohol-related health harms and their impact on life chances, including the establishment of specialist alcohol care teams in hospitals and support children of alcohol dependent parents.
The new Office for Health Improvement and Disparities will lead our efforts to improve treatment and support, with £80 million of new investment. We have also committed to publish a new United Kingdom-wide cross-Government addiction strategy which will consider a range of issues, including drugs, alcohol and problem gambling. We will consider the emerging evidence around increased alcohol harms during the pandemic and what further action is needed as we develop the strategy.
Asked by: Wayne David (Labour - Caerphilly)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions he has had with the (a) Welsh Government and (b) other devolved Administrations on ensuring there is parity of support for all victims of the contaminated blood scandal across the UK.
Answered by Nadine Dorries
My Rt. hon Friend the Secretary of State for Health and Social Care recently met with his counterparts in the devolved administrations to discuss this issue.
Asked by: Wayne David (Labour - Caerphilly)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what plans his Department has to improve the diagnosis and treatment of neurofibromatosis.
Answered by Caroline Dinenage
NHS England has commissioned a national specialised service to address the healthcare needs of neurofibromatosis type 1 (NF1) patients with rare complications that cause major health problems (called complex-NF1). There are two centres responsible for the diagnosis and long-term care of complex NF1 which are based at Guy’s and St Thomas’ NHS Foundation Trust and Central Manchester University Hospitals NHS Foundation Trust. These centres also provide education with the National Health Service to raise and maintain awareness of NF1 and are expected to form a relationship with local health and social care providers to help optimise any care for complex NF1 patients provided locally.
In 2010, a nationally funded service was established for patients in England with a diagnosis of neurofibromatosis type 2 (NF2). The purpose of this service is to ensure patients are managed consistently by experienced doctors within a multi-disciplinary setting and that they receive the highest standard of care. The service for NF2 is co-ordinated from four major clinic centres: Manchester, Cambridge, Oxford and London. Each centre has a clearly defined geographical area of responsibility and runs peripheral clinics within that area, contributing their expertise to ensure the same standard of service and care is maintained.
Over the last few years, there has been an increase in the awareness of NF through more training of doctors and nurses, particularly through community paediatricians, development of guidelines with nurses, and links with genetic and neurology clinics. Links between expert centres have developed and improved the transfer of patients whose condition is complex to the centres. Professionals at the expert centres including consultants and specialist nurses also undertake the usual range of activities to raise awareness of the condition by giving lectures and presentations, attending conferences and publishing papers in medical journals.
In April 2018, the former Parliamentary Under Secretary of State for Public Health and Primary Care (Steve Brine MP) met the Childhood Tumour Trust to discuss, amongst other things, raising awareness of NF.
Asked by: Wayne David (Labour - Caerphilly)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions his Department has had with neurofibromatosis charities to help raise awareness of the condition.
Answered by Caroline Dinenage
NHS England has commissioned a national specialised service to address the healthcare needs of neurofibromatosis type 1 (NF1) patients with rare complications that cause major health problems (called complex-NF1). There are two centres responsible for the diagnosis and long-term care of complex NF1 which are based at Guy’s and St Thomas’ NHS Foundation Trust and Central Manchester University Hospitals NHS Foundation Trust. These centres also provide education with the National Health Service to raise and maintain awareness of NF1 and are expected to form a relationship with local health and social care providers to help optimise any care for complex NF1 patients provided locally.
In 2010, a nationally funded service was established for patients in England with a diagnosis of neurofibromatosis type 2 (NF2). The purpose of this service is to ensure patients are managed consistently by experienced doctors within a multi-disciplinary setting and that they receive the highest standard of care. The service for NF2 is co-ordinated from four major clinic centres: Manchester, Cambridge, Oxford and London. Each centre has a clearly defined geographical area of responsibility and runs peripheral clinics within that area, contributing their expertise to ensure the same standard of service and care is maintained.
Over the last few years, there has been an increase in the awareness of NF through more training of doctors and nurses, particularly through community paediatricians, development of guidelines with nurses, and links with genetic and neurology clinics. Links between expert centres have developed and improved the transfer of patients whose condition is complex to the centres. Professionals at the expert centres including consultants and specialist nurses also undertake the usual range of activities to raise awareness of the condition by giving lectures and presentations, attending conferences and publishing papers in medical journals.
In April 2018, the former Parliamentary Under Secretary of State for Public Health and Primary Care (Steve Brine MP) met the Childhood Tumour Trust to discuss, amongst other things, raising awareness of NF.